Zasocitinib (TAK-279) is Takeda's once-daily oral allosteric TYK2 inhibitor, under U.S. FDA priority review for moderate to severe plaque psoriasis.
Competing Products
Takeda
Takeda Ventures: A global investment firm specializing in technology and biopharmaceutical ventures.
Founded
1781Takeda Ventures, Inc. is the venture investment arm of Takeda, a global biopharmaceutical leader. Founded to drive innovation in technology and biopharmaceuticals, its core mission is to identify and invest in groundbreaking technologies and product concepts that can advance healthcare globally. The firm focuses on early-stage investments in companies developing novel therapeutics and platform technologies, aiming to foster advancements that align with Takeda's broader vision of improving patient health worldwide.
Notable affiliates of Takeda Ventures include its parent company, Takeda Pharmaceutical Company Limited, a renowned entity in the biopharmaceutical industry. The firm has made significant strides in supporting pioneering startups and technologies, contributing to the development of impactful medical treatments. Key achievements include successful investments in companies that have progressed to clinical trials and market launches. Overall, Takeda Ventures has established itself as a crucial player in the biopharmaceutical investment landscape, driving innovation and enhancing global healthcare outcomes.
Takeda - M & A Snapshot
Takeda - Quick Facts
Who are Takeda's competitors?
Companies similar to Takeda include Amgen, Bristol Myers Squibb, InnoCare Pharma and Alumis.
When was Takeda founded?
Takeda was founded in 1781.
Where is Takeda's headquarters located?
Takeda's headquarters is located in San Diego, CA, US.
When was Takeda's last funding round?
Takeda's most recent funding round was for $19.8M (USD) in September 2016.
